Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
- Achieved >90% degradation across multiple species with low oral doses
- Demonstrated superior efficacy to current standards in lupus and RA models
- Showed favorable safety profile up to 200-fold projected human efficacious levels
- Effectively blocked multiple inflammatory pathways in patient samples
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in the BofA Securities 2025 Healthcare Conference. The company will engage in a fireside chat on May 14, 2025, at 3:40 p.m. PT in Las Vegas, NV. Investors can access a live webcast of the presentation through the \"News and Events\" section of Kymera's website, with a replay available after the event.
Kymera Therapeutics (NASDAQ: KYMR) has scheduled a video webcast for May 9, 2025, from 10:00 a.m. to 11:30 a.m. ET. During this event, the clinical-stage biopharmaceutical company will:
- Present its Q1 2025 financial results
- Unveil a new oral development candidate targeting an undrugged target for autoimmune and rheumatic diseases
- Review highlights and upcoming milestones of its immunology pipeline
The webcast will be accessible through registration and available for replay on the company's website under the Investors section.
Kymera Therapeutics (NASDAQ: KYMR) has initiated dosing in its BroADen Phase 1b clinical trial for KT-621, a first-in-class oral STAT6 degrader, targeting moderate to severe atopic dermatitis (AD). The trial will evaluate approximately 20 adult patients with once-daily dosing for 28 days, focusing on safety, tolerability, and clinical activity.
The company has completed SAD/MAD dosing in the Phase 1 healthy volunteer trial, with data expected in June 2025. The BroADen trial results are anticipated in Q4 2025. Additionally, Kymera plans to launch two parallel Phase 2b trials: one for AD in Q4 2025 and another for asthma in Q1 2026.
The BroADen study aims to demonstrate that STAT6 degradation in blood and skin by KT-621 produces effects similar to dupilumab in reducing Th2 biomarkers. The trial will assess clinical endpoints including Eczema Area and Severity Index (EASI) and pruritus numerical rating scale (NRS).
Kymera Therapeutics (NASDAQ: KYMR) has appointed Noah Goodman, M.B.A., as Chief Business Officer to lead business development strategy and activities. Goodman brings extensive life sciences industry experience, having previously served as President and Chief Business Officer at Chroma Medicine and nChroma Bio through their merger with Nvelop Therapeutics.
Prior to joining Kymera, Goodman held key positions at several biotech companies, including Executive Director roles at Cadent Therapeutics (later acquired by Novartis) and Seres Therapeutics, where he led collaborations and licensing transactions. His earlier experience includes business development at Spark Therapeutics and consulting at Easton Associates.
The appointment aligns with Kymera's mission to develop oral small molecule degrader medicines for immunological diseases and build a fully integrated biopharmaceutical company.
Kymera Therapeutics (NASDAQ: KYMR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its immunology pipeline. The company maintains a strong financial position with $851 million in cash as of December 31, 2024, providing runway into mid-2027.
Key pipeline updates include: KT-621 (STAT6) Phase 1 trial data expected June 2025, with Phase 1b trial in atopic dermatitis starting Q2 2025; KT-295 (TYK2) Phase 1 trial initiating Q2 2025; and ongoing KT-474/SAR444656 (IRAK4) Phase 2b trials in partnership with Sanofi.
Financial results show collaboration revenues of $7.4 million for Q4 2024 and $47.1 million for full-year 2024. Net loss was $70.8 million for Q4 and $223.9 million for the full year. R&D expenses increased to $240.2 million for 2024, reflecting investment in pipeline development.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in several key investor conferences in March 2025.
The company will engage in fireside chats at the following events:
- TD Cowen 45th Annual Healthcare Conference in Boston (March 5, 9:10 a.m. ET)
- Leerink Partners Global Biopharma Conference in Miami (March 11, 8:00 a.m. ET)
- Jefferies Biotech on the Bay Summit in Miami (March 12, one-on-one meetings)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (March 27, 10:30 a.m. ET)
Live webcasts will be accessible through the Investors section of Kymera's website, with replays available after the events.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines, has announced it will release its fourth quarter and full year 2024 financial results on February 27, 2025. The company will host a video conference call at 8:30 a.m. ET on the same day. Investors can access the video call through registration or view the livestreamed webcast in the 'News and Events' section of Kymera's website. A replay of the webcast will be available after the event.